Discover
EOLS
Evolus, Inc.
6.74
2 x 5.01
2 x 8.67
bid
ask
-
0.20
2.88%
2 @ 05:10 AM
6.74 +0.00 (0.00%)
| Ytd | 1.35% | |
| 1y | -26.74% |
6.70
day range
7.05
3.86
52 week range
10.20
| Open | 7.03 | Prev Close | 6.94 | Low | 6.70 | High | 7.05 | Mkt Cap | 443.86M |
| Vol | 567.58K | Avg Vol | 826.42K | EPS | -0.66 | P/E | N/A | Forward P/E | 54.20 |
| Beta | 1.31 | Short Ratio | 7.38 | Inst. Own | 80.22% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-04 | 50-d Avg | 6.32 | 200-d Avg | 5.89 | 1yr Est | 23.43 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-06 | 2024-09 | -0.08 | -0.19 | -0.11 | -137.50% |
| 2024-07-31 | 2024-06 | -0.04 | -0.07 | -0.03 | -75.00% |
| 2024-07-31 | 2024-06 | -0.04 | N/A | N/A | N/A |
| 2024-05-07 | 2024-03 | -0.07 | -0.13 | -0.06 | -85.71% |
| 2024-05-07 | 2024-03 | -0.07 | N/A | N/A | N/A |
| 2024-03-07 | 2023-12 | -0.07 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-11-07 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-11-01 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-10-03 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-09-16 | Cantor Fitzgerald | Upgrade | Overweight | |
| 2024-09-13 | Barclays | Upgrade | Overweight | Overweight |
| 2024-09-13 | Needham | Upgrade | Buy | Buy |
Profile
Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Nuceiva, for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-05-09 | AVELAR RUI L. | Officer | 368.85K | Sale |
| 2024-09-05 | BEAVER SANDRA | Chief Financial Officer | 148.50K | Sale |
| 2024-02-06 | BLANK SIMONE | Director | 552.53K | Stock Award(Grant) |
| 2024-05-13 | GILL DAVID N. | Director | 33.96K | Sale |
| 2024-02-06 | HAYMAN ROBERT | Director | 65.22K | Stock Award(Grant) |
| 2024-06-02 | MALIK VIKRAM | Director | 246.51K | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Perceptive Advisors Llc | 5.36M | 58.07M | 8.46% |
| 2024-09-29 | Tang Capital Management, LLC | 4.85M | 52.55M | 7.66% |
| 2024-09-29 | Blackrock Inc. | 4.23M | 45.85M | 6.68% |
| 2024-09-29 | Vanguard Group Inc | 3.20M | 34.64M | 5.05% |
| 2024-09-29 | Nantahala Capital Management, LLC | 2.82M | 30.62M | 4.46% |
| 2024-09-29 | Caligan Partners, LP | 2.19M | 23.78M | 3.46% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 1.68M | 18.26M | 2.66% |
| 2024-10-30 | iShares Russell 2000 ETF | 1.42M | 15.42M | 2.25% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 708.63K | 7.68M | 1.12% |
| 2024-08-30 | Fidelity Small Cap Index Fund | 564.79K | 6.12M | 0.89% |
| 2024-09-29 | Oberweis Micro-Cap Portfolio | 514.90K | 5.58M | 0.81% |
| 2024-10-30 | iShares Russell 2000 Growth ETF | 492.52K | 5.34M | 0.78% |